Cell Source, Inc.
CLCS · OTC
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $361 | $361 | $820 | $356 |
| G&A Expenses | $0 | $471 | $374 | $782 |
| SG&A Expenses | $324 | $471 | $374 | $782 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $685 | $832 | $1,194 | $1,138 |
| Operating Income | -$685 | -$832 | -$1,194 | -$1,138 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $95 | -$586 | -$295 | -$137 |
| Pre-Tax Income | -$590 | -$1,417 | -$1,489 | -$1,275 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$590 | -$1,417 | -$1,489 | -$1,275 |
| % Margin | – | – | – | – |
| EPS | -0.021 | -0.042 | -0.045 | -0.04 |
| % Growth | 49.6% | 6.5% | -12.9% | – |
| EPS Diluted | -0.021 | -0.042 | -0.045 | -0.04 |
| Weighted Avg Shares Out | 45,038 | 42,426 | 41,019 | 40,507 |
| Weighted Avg Shares Out Dil | 45,038 | 42,426 | 41,019 | 40,507 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $214 | $505 | $306 | $143 |
| Depreciation & Amortization | $0 | -$81 | $11 | $0 |
| EBITDA | -$376 | -$912 | -$1,172 | -$1,132 |
| % Margin | – | – | – | – |